New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSS-31 (Elamipretide) vs MGF (Mechano Growth Factor)

SS-31 (Elamipretide) vs MGF (Mechano Growth Factor)

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
SS-31 (Elamipretide)
Anabolic & IGF
MGF (Mechano Growth Factor)
Summary
SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
Half-Life
~2–5 hours
Native MGF: minutes. PEG-MGF: ~3 days
Admin Route
SubQ
SubQ, IM
Research
Typical Dose
5–10 mg
200–400 mcg
Frequency
Daily to several times per week
1–2 times per week
Key Benefits
  • Restores mitochondrial function and ATP production
  • Protects inner mitochondrial membrane cardiolipin
  • Reduces mitochondrial reactive oxygen species (ROS)
  • Improves exercise capacity and reduces fatigue
  • Cardioprotective — studied in heart failure trials
  • Renoprotective — reduces ischemic kidney injury
  • Anti-aging via mitochondrial preservation
  • Potential in neurodegenerative disease prevention
  • Activates muscle satellite cells for repair and growth
  • Accelerates recovery from muscle damage
  • Synergistic with IGF-1 LR3 (different mechanisms)
  • Promotes muscle hypertrophy specifically at exercised muscles
  • Faster recovery between training sessions
  • Potential for injury repair in connective tissue
Side Effects
  • Injection site irritation
  • Nausea (rare)
  • Generally well-tolerated in clinical trials
  • Muscle soreness (satellite cell activation)
  • Injection site irritation
  • Hypoglycemia risk (modest, less than IGF-1 LR3)
Stacks With